Eli Lilly and Company Company Profile (NYSE:LLY)

About Eli Lilly and Company

Eli Lilly and Company logoEli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, such as Humalog and Humalog Mix 75/25; neuroscience products, such as Cymbalta and Zyprexa; oncology products, such as Alimta and Cyramza, and cardiovascular products, such as Cialis and ReoPro. The Company's animal health products segment includes products for food animals, such as Rumensin and Posilac; products for companion animals, such as Onsior and Osurnia, and Novartis Animal Health (Novartis AH) products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: LLY
  • CUSIP: 53245710
Key Metrics:
  • Previous Close: $80.39
  • 50 Day Moving Average: $76.79
  • 200 Day Moving Average: $76.67
  • 52-Week Range: $1,072,099,000.00 - $64.18
  • Trailing P/E Ratio: 31.18
  • Foreward P/E Ratio: 18.31
  • P/E Growth: 1.73
  • Market Cap: $86.19B
  • Outstanding Shares: 1,072,099,000
  • Beta: 0.3
  • Net Margins: 12.90%
  • Return on Equity: 24.74%
  • Return on Assets: 10.30%
  • Debt-to-Equity Ratio: 0.56%
  • Current Ratio: 1.62%
  • Quick Ratio: 1.15%
Additional Links:
Companies Related to Eli Lilly and Company:

Analyst Ratings

Consensus Ratings for Eli Lilly and Company (NYSE:LLY) (?)
Ratings Breakdown: 3 Hold Ratings, 11 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.87)
Consensus Price Target: $87.45 (8.79% upside)

Analysts' Ratings History for Eli Lilly and Company (NYSE:LLY)
DateFirmActionRatingPrice TargetDetails
2/17/2017Jefferies Group LLCReiterated RatingBuyView Rating Details
2/1/2017Barclays PLCBoost Price TargetBuy$80.00 -> $85.00View Rating Details
2/1/2017BMO Capital MarketsReiterated RatingMarket Perform$70.00 -> $73.00View Rating Details
1/19/2017Citigroup Inc.Set Price TargetBuy$100.00View Rating Details
1/18/2017Goldman Sachs Group, Inc. (The)Reiterated RatingConviction-Buy$92.00View Rating Details
1/18/2017Credit Suisse GroupReiterated RatingOutperform$87.00View Rating Details
12/16/2016Morgan StanleyUpgradeEqual Weight -> Overweight$73.00 -> $82.00View Rating Details
12/7/2016Sanford C. BernsteinReiterated RatingOverweightView Rating Details
11/26/2016Leerink SwannReiterated RatingOutperform$102.00 -> $92.00View Rating Details
11/26/2016J P Morgan Chase & CoReiterated RatingOverweightView Rating Details
11/25/2016Atlantic SecuritiesDowngradeOverweight -> NeutralView Rating Details
10/27/2016Societe GeneraleReiterated RatingHold$78.00View Rating Details
9/20/2016Deutsche Bank AGReiterated RatingBuyView Rating Details
8/2/2016ArgusBoost Price TargetBuy$90.00 -> $95.00View Rating Details
6/15/2016SunTrust Banks, Inc.Reiterated RatingBuyView Rating Details
2/4/2016Berenberg BankBoost Price TargetBuy$105.00 -> $106.00View Rating Details
12/22/2015Bank of America CorpReiterated RatingBuy$104.00 -> $108.00View Rating Details
12/9/2015Piper Jaffray CompaniesReiterated RatingBuyView Rating Details
8/21/2015Cowen and CompanyReiterated RatingOutperform$92.00View Rating Details
2/23/2015Tigress FinancialReiterated RatingBuyView Rating Details
(Data available from 2/21/2015 forward)


Earnings History for Eli Lilly and Company (NYSE:LLY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/31/2017Q416$0.98$0.95$5.54 billion$5.76 billionViewN/AView Earnings Details
10/25/2016Q316$0.96$0.88$4.23 billion$5.19 billionViewListenView Earnings Details
7/26/2016Q216$0.86$0.86$5.14 billion$5.40 billionViewListenView Earnings Details
4/26/2016Q116$0.85$0.83$4.82 billion$4.87 billionViewListenView Earnings Details
1/28/2016Q415$0.78$0.78$5.33 billion$5.38 billionViewListenView Earnings Details
10/22/2015Q315$0.76$0.89$4.99 billion$4.96 billionViewListenView Earnings Details
7/23/2015Q215$0.74$0.90$4.89 billion$4.98 billionViewListenView Earnings Details
4/23/2015Q115$0.76$0.87$4.62 billion$4.64 billionViewN/AView Earnings Details
1/30/2015Q414$0.74$0.75$5.21 billion$5.12 billionViewN/AView Earnings Details
10/23/2014Q314$0.67$0.66$4.83 billion$4.88 billionViewListenView Earnings Details
7/24/2014Q214$0.65$0.68$4.88 billion$4.94 billionViewN/AView Earnings Details
4/24/2014Q114$0.70$0.70$4.78 billion$4.68 billionViewN/AView Earnings Details
1/30/2014Q413$0.72$0.74$5.46 billion$5.81 billionViewListenView Earnings Details
10/23/2013Q313$1.04$1.11$5.76 billion$5.77 billionViewN/AView Earnings Details
7/24/2013Q2 2013$1.01$1.16$5.82 billion$5.93 billionViewN/AView Earnings Details
4/24/2013Q1 2013$1.05$1.14$5.66 billion$5.60 billionViewN/AView Earnings Details
1/29/2013Q4 2012$0.82$0.85$5.78 billion$5.96 billionViewN/AView Earnings Details
10/24/2012$0.82$0.79ViewN/AView Earnings Details
7/25/2012$0.76$0.83ViewN/AView Earnings Details
4/25/2012$0.80$0.92ViewN/AView Earnings Details
1/31/2012$0.80$0.87ViewN/AView Earnings Details
10/20/2011$1.12$1.13ViewN/AView Earnings Details
7/21/2011$1.18$1.18ViewN/AView Earnings Details
4/18/2011$1.16$1.24ViewN/AView Earnings Details
1/27/2011$1.10$1.11ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Eli Lilly and Company (NYSE:LLY)
Current Year EPS Consensus Estimate: $4.10 EPS
Next Year EPS Consensus Estimate: $4.39 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.80$0.86$0.83
Q2 20163$0.85$0.88$0.86
Q3 20163$0.90$0.98$0.93
Q4 20162$0.92$0.99$0.96
Q1 20171$0.98$0.98$0.98
Q2 20171$1.05$1.05$1.05
Q3 20171$1.04$1.04$1.04
Q4 20171$1.02$1.02$1.02
(Data provided by Zacks Investment Research)


Current Dividend Information for Eli Lilly and Company (NYSE:LLY)
Annual Dividend:$2.08
Dividend Yield:2.59%
Dividend Growth:1.30% (3 Year Average)
Payout Ratio:80.62% (Based on Trailing 12 Months of Earnings)
50.73% (Based on Current Year Consensus EPS Estimate)
47.38% (Based on Next Year Consensus EPS Estimate)
Track Record:2 Years of Consecutive Dividend Growth

Dividend History for Eli Lilly and Company (NYSE:LLY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Eli Lilly and Company (NYSE:LLY)
Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 75.15%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/6/2017Alfonso G ZuluetaSVPSell15,000$77.66$1,164,900.00View SEC Filing  
2/3/2017Derica W RiceEVPSell11,162$77.14$861,036.68View SEC Filing  
2/2/2017Donald A ZakrowskiInsiderSell2,000$77.52$155,040.00View SEC Filing  
2/1/2017Lilly Endowment IncMajor ShareholderSell220,000$77.35$17,017,000.00View SEC Filing  
12/16/2016Lilly Endowment IncMajor ShareholderSell200,000$72.59$14,518,000.00View SEC Filing  
12/16/2016Melissa S BarnesInsiderSell2,093$82.23$172,107.39View SEC Filing  
12/16/2016R David HooverDirectorBuy500$71.85$35,925.00View SEC Filing  
12/16/2016Susan MahonySVPSell20,242$72.65$1,470,581.30View SEC Filing  
10/5/2016Maria A CroweInsiderSell2,248$81.37$182,919.76View SEC Filing  
8/15/2016Jackson P TaiDirectorBuy5,773$80.43$464,322.39View SEC Filing  
8/12/2016Jackson P TaiDirectorBuy2,560$80.42$205,875.20View SEC Filing  
7/29/2016Lilly Endowment IncMajor ShareholderSell205,000$82.94$17,002,700.00View SEC Filing  
7/28/2016Donald A ZakrowskiInsiderSell1,213$83.16$100,873.08View SEC Filing  
7/28/2016Lilly Endowment IncMajor ShareholderSell240,000$82.87$19,888,800.00View SEC Filing  
7/12/2016Lilly Endowment IncMajor ShareholderSell210,000$79.54$16,703,400.00View SEC Filing  
7/7/2016Lilly Endowment IncMajor ShareholderSell225,000$79.14$17,806,500.00View SEC Filing  
6/30/2016Lilly Endowment IncMajor ShareholderSell215,000$78.46$16,868,900.00View SEC Filing  
6/29/2016Lilly Endowment IncMajor ShareholderSell220,000$77.86$17,129,200.00View SEC Filing  
6/10/2016Melissa S BarnesSVPSell992$73.77$73,179.84View SEC Filing  
5/31/2016Lilly Endowment IncMajor ShareholderSell200,000$75.12$15,024,000.00View SEC Filing  
5/12/2016Jackson P TaiDirectorBuy1,080$75.75$81,810.00View SEC Filing  
5/12/2016Lilly Endowment IncMajor ShareholderSell190,000$75.86$14,413,400.00View SEC Filing  
5/2/2016Donald A ZakrowskiCAOSell1,600$75.86$121,376.00View SEC Filing  
4/29/2016Lilly Endowment IncMajor ShareholderSell180,000$75.44$13,579,200.00View SEC Filing  
4/27/2016Alfonso G ZuluetaSVPSell12,000$76.27$915,240.00View SEC Filing  
4/8/2016Lilly Endowment IncMajor ShareholderSell200,000$74.29$14,858,000.00View SEC Filing  
2/5/2016Stephen F FrySVPSell15,230$78.87$1,201,190.10View SEC Filing  
2/3/2016David A. RicksSVPSell5,733$77.66$445,224.78View SEC Filing  
2/3/2016Derica W. RiceCFOSell10,483$77.78$815,367.74View SEC Filing  
2/1/2016Jackson P TaiDirectorBuy3,170$78.62$249,225.40View SEC Filing  
1/29/2016Alfonso G ZuluetaSVPSell5,000$78.75$393,750.00View SEC Filing  
12/21/2015Lilly Endowment IncMajor ShareholderSell205,000$86.00$17,630,000.00View SEC Filing  
12/15/2015Lilly Endowment IncMajor ShareholderSell215,000$85.60$18,404,000.00View SEC Filing  
12/9/2015Enrique A ConternoVPSell25,000$83.88$2,097,000.00View SEC Filing  
12/2/2015Lilly Endowment Incmajor shareholderSell210,000$85.09$17,868,900.00View SEC Filing  
11/20/2015Lilly Endowment Incmajor shareholderSell205,000$84.54$17,330,700.00View SEC Filing  
10/29/2015Lilly Endowment Incmajor shareholderSell200,000$82.28$16,456,000.00View SEC Filing  
10/9/2015Lilly Endowment Incmajor shareholderSell215,000$85.86$18,459,900.00View SEC Filing  
10/5/2015Lilly Endowment Incmajor shareholderSell260,000$86.46$22,479,600.00View SEC Filing  
9/18/2015Lilly Endowment Incmajor shareholderSell250,000$89.04$22,260,000.00View SEC Filing  
6/10/2015Lilly Endowment IncMajor ShareholderSell210,000$82.39$17,301,900.00View SEC Filing  
6/4/2015Lilly Endowment IncMajor ShareholderSell200,000$77.90$15,580,000.00View SEC Filing  
5/29/2015Jeffrey N SimmonsSVPSell20,000$78.08$1,561,600.00View SEC Filing  
5/20/2015Lilly Endowment IncMajor ShareholderSell190,000$73.43$13,951,700.00View SEC Filing  
5/15/2015Lilly Endowment IncMajor ShareholderSell200,000$72.83$14,566,000.00View SEC Filing  
5/8/2015Lilly Endowment IncMajor ShareholderSell195,000$73.28$14,289,600.00View SEC Filing  
5/1/2015Lilly Endowment IncMajor ShareholderSell200,000$73.09$14,618,000.00View SEC Filing  
3/30/2015Lilly Endowment IncMajor ShareholderSell180,000$73.94$13,309,200.00View SEC Filing  
3/23/2015Lilly Endowment IncMajor ShareholderSell190,000$76.97$14,624,300.00View SEC Filing  
3/9/2015Stephen F FrySVPSell4,000$69.27$277,080.00View SEC Filing  
2/4/2015David A RicksSVPSell3,147$69.99$220,258.53View SEC Filing  
2/4/2015Derica W RiceCFOSell5,316$70.00$372,120.00View SEC Filing  
2/4/2015Jan M LundbergEVPSell11,085$70.08$776,836.80View SEC Filing  
2/3/2015Jan M LundbergEVPSell121,711$70.78$8,614,704.58View SEC Filing  
2/2/2015David A RicksSVPSell4,769$71.51$341,031.19View SEC Filing  
2/2/2015Derica W RiceCFOSell10,068$71.84$723,285.12View SEC Filing  
12/4/2014Lilly Endowment IncMajor ShareholderSell190,000$71.92$13,664,800.00View SEC Filing  
12/2/2014Lilly Endowment IncMajor ShareholderSell180,000$70.14$12,625,200.00View SEC Filing  
11/13/2014Lilly Endowment IncMajor ShareholderSell200,000$67.73$13,546,000.00View SEC Filing  
11/5/2014Lilly Endowment IncMajor ShareholderSell180,000$67.00$12,060,000.00View SEC Filing  
11/4/2014Fionnuala M WalshSVPSell15,000$67.00$1,005,000.00View SEC Filing  
11/3/2014Enrique A ConternoVPSell5,000$66.03$330,150.00View SEC Filing  
10/31/2014Fionnuala M WalshSVPSell7,376$66.58$491,094.08View SEC Filing  
10/31/2014Lilly Endowment IncMajor ShareholderSell190,000$66.40$12,616,000.00View SEC Filing  
10/30/2014Lilly Endowment IncMajor ShareholderSell175,000$66.58$11,651,500.00View SEC Filing  
10/24/2014Maria A CroweInsiderSell2,750$65.77$180,867.50View SEC Filing  
10/6/2014Lilly Endowment IncMajor ShareholderSell210,000$65.63$13,782,300.00View SEC Filing  
10/1/2014Enrique A ConternoVPSell5,000$64.86$324,300.00View SEC Filing  
9/30/2014Lilly Endowment IncMajor ShareholderSell200,000$65.07$13,014,000.00View SEC Filing  
9/10/2014Lilly Endowment IncMajor ShareholderSell210,000$64.77$13,601,700.00View SEC Filing  
9/3/2014Lilly Endowment IncMajor ShareholderSell200,000$63.99$12,798,000.00View SEC Filing  
9/2/2014Enrique A ConternoVPSell5,000$63.60$318,000.00View SEC Filing  
7/29/2014Lilly Endowment IncMajor ShareholderSell250,000$63.03$15,757,500.00View SEC Filing  
7/28/2014Susan MahonySVPSell2,065$63.30$130,714.50View SEC Filing  
7/25/2014Enrique A ConternoVPSell10,000$63.79$637,900.00View SEC Filing  
7/25/2014Susan MahonySVPSell30,000$63.90$1,917,000.00View SEC Filing  
7/1/2014Lilly Endowment IncMajor ShareholderSell235,000$62.30$14,640,500.00View SEC Filing  
6/25/2014Lilly Endowment IncMajor ShareholderSell245,000$62.68$15,356,600.00View SEC Filing  
6/20/2014Lilly Endowment IncMajor ShareholderSell230,000$61.55$14,156,500.00View SEC Filing  
6/16/2014Lilly Endowment IncMajor ShareholderSell200,000$58.73$11,746,000.00View SEC Filing  
6/5/2014Lilly Endowment IncMajor ShareholderSell190,000$59.53$11,310,700.00View SEC Filing  
5/21/2014Lilly Endowment Incmajor shareholderSell230,000$58.90$13,547,000.00View SEC Filing  
5/12/2014Jackson TaiDirectorBuy17,157$59.19$1,015,522.83View SEC Filing  
5/12/2014Lilly Endowment Incmajor shareholderSell210,000$59.33$12,459,300.00View SEC Filing  
5/6/2014Lilly Endowment Incmajor shareholderSell190,000$58.79$11,170,100.00View SEC Filing  
4/29/2014Lilly Endowment Incmajor shareholderSell200,000$59.43$11,886,000.00View SEC Filing  
4/28/2014Lilly Endowment Incmajor shareholderSell150,000$58.64$8,796,000.00View SEC Filing  
8/15/2013Enrique ConternoVPSell5,000$53.79$268,950.00View SEC Filing  
7/29/2013Jacques TapieroSVPSell7,500$53.74$403,050.00View SEC Filing  
7/15/2013Enrique A ConternoVPSell5,000$51.43$257,150.00View SEC Filing  
6/17/2013Enrique A ConternoVPSell5,000$52.45$262,250.00View SEC Filing  
5/15/2013Enrique A ConternoVPSell5,000$56.15$280,750.00View SEC Filing  
5/10/2013Jeffrey N SimmonsSVPSell10,000$54.49$544,900.00View SEC Filing  
3/26/2013Susan MahonySVPSell5,000$56.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Eli Lilly and Company (NYSE:LLY)
marketrealist.com logoThese Prescription Products Matter to Sanofi’s Growth (NYSE:LLY)
marketrealist.com - February 20 at 5:44 PM
fool.com logoBetter Buy: Eli Lilly and Company vs. Johnson & Johnson - Motley Fool (NYSE:LLY)
www.fool.com - February 20 at 10:19 AM
News IconWellbutrin For Anxiety - Wellbutrin And Alcohol - Wellbutrin For Smoking Cessation - 6,278 Completed ORDERS Today! (NYSE:LLY)
www.joesdaily.com - February 19 at 5:28 PM
News IconHomemade Viagra - Tadalafil 20Mg - Do You Need A Prescription For Viagra - 7,770 Completed ORDERS Today! (NYSE:LLY)
www.bmwcoop.com - February 19 at 5:28 PM
News IconBuy Cialis Generic onlie price - cialis purchase online - purchase cialis online canada - 2,195 Completed ORDERS Today! (NYSE:LLY)
www.prettyprudent.com - February 19 at 5:28 PM
News IconFlonase Nasal Spray - Flonase Coupon - Flonase Dosage - 9,846 Completed ORDERS Today! (NYSE:LLY)
gamingillustrated.com - February 19 at 5:28 PM
News IconCialis For Daily Use - Pills Amazon - Pills For Dogs - 7,232 Completed ORDERS Today! (NYSE:LLY)
www.littlesunnykitchen.com - February 19 at 5:28 PM
News IconGeneric Viagra Without A Doctor Prescription - best generic cialis - best place to buy cialis - 1,443 Completed ORDERS Today! (NYSE:LLY)
www.popinsomniacs.com - February 19 at 5:28 PM
News IconPrevacid Dosage - Prevacid Solutab - Prevacid Infants - 8,313 Completed ORDERS Today! (NYSE:LLY)
www.profkrg.com - February 19 at 10:04 AM
News IconUk Pharmacy - Community Pharmacy Madison - Rite Aid Pharmacy Los Angeles Ca - 5,572 Completed ORDERS Today! (NYSE:LLY)
conversationalreading.com - February 19 at 10:04 AM
News IconOnline Pharmacy - Canadian Pharmacies - Viagra Generic - 2,380 Completed ORDERS Today! (NYSE:LLY)
hpherald.com - February 19 at 10:04 AM
News IconMircette Generic - Mircette Estrogen - Mircette Hair Loss - 5,260 Completed ORDERS Today! (NYSE:LLY)
www.hollywoodnewsdaily.com - February 19 at 10:04 AM
News IconViagra Vs Cialis - How Long Does Viagra Last - 24 Hour Pharmacy - 8,319 Completed ORDERS Today! (NYSE:LLY)
arseblog.com - February 19 at 10:04 AM
News IconCialis Com - Stendra Vs Viagra - Can Women Take Viagra - 3,529 Completed ORDERS Today! (NYSE:LLY)
gamingillustrated.com - February 19 at 10:04 AM
News IconCialis Vs Viagra - cialis for sale online - cialis pills for sale - 1,565 Completed ORDERS Today! (NYSE:LLY)
www.paintedteacup.com - February 18 at 5:35 PM
News IconGreenfield Pharmacy - Wayne Pharmacy Goldsboro Nc - Marion Pharmacy - 3,156 Completed ORDERS Today! (NYSE:LLY)
www.bmwcoop.com - February 18 at 5:35 PM
News IconCytoxan And Avastin - Cytotec Abortion - Cytotec For Miscarriage - 8,752 Completed ORDERS Today! (NYSE:LLY)
www.netnewsledger.com - February 18 at 5:35 PM
News IconViagra Online - Liquid Cialis - Cheap Viagra Online - 7,454 Completed ORDERS Today! (NYSE:LLY)
conversationalreading.com - February 18 at 5:35 PM
News IconHighly Traded Stock: Eli Lilly and Company (NYSE:LLY) (NYSE:LLY)
hoyentv.com - February 18 at 5:35 PM
News IconEli Lilly and Company (NYSE:LLY) Stock Technicals Hit Strength (NYSE:LLY)
mundoaguaysaneamiento.net - February 18 at 5:35 PM
News IconBetter Buy: Eli Lilly and Company vs. Johnson & Johnson - Bloomington Pantagraph (NYSE:LLY)
www.pantagraph.com - February 18 at 11:58 AM
fool.com logoBetter Buy: Eli Lilly and Company vs. Johnson & Johnson (NYSE:LLY)
www.fool.com - February 18 at 7:58 AM
News IconViagra Generic onlie coupon - online generic cialis - buy cialis generic online - 6,449 Completed ORDERS Today! (NYSE:LLY)
cwmemory.com - February 17 at 4:29 PM
finance.yahoo.com logoMerrimack (MACK): What Awaits the Stock in Q4 Earnings? (NYSE:LLY)
finance.yahoo.com - February 17 at 4:29 PM
News IconAshburton Jersey Ltd Lowers Position in Eli Lilly and Company (LLY) (NYSE:LLY)
prensariotiretail.com - February 17 at 4:29 PM
News IconEli Lilly and Company (NYSE:LLY) (NYSE:LLY)
oakridgeobserver.com - February 17 at 4:29 PM
us.rd.yahoo.com logoMerck (MRK) Halts Late Stage Alzheimer Study; Shares Slip (NYSE:LLY)
us.rd.yahoo.com - February 17 at 4:29 PM
News IconAnalysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Merus NV (NASDAQ: MRUS) and Shire ... - Analyst Ratings (NYSE:LLY)
www.analystratings.com - February 17 at 8:29 AM
News IconTaking a Look at the Chart for Eli Lilly and Company (LLY) - The USA Commerce (NYSE:LLY)
theusacommerce.com - February 17 at 8:29 AM
News IconJust the Facts on Eli Lilly and Company (LLY) - StockNewsJournal (NYSE:LLY)
stocknewsjournal.com - February 17 at 8:29 AM
News IconHow Long Does Viagra Take To Work - Canada Pharmacy Online - Viagra Definition - 6,112 Completed ORDERS Today! (NYSE:LLY)
www.hollywoodnewsdaily.com - February 16 at 10:53 PM
News IconLevitra 20 Mg - Generic Viagra Online - Herbal Viagra - 6,741 Completed ORDERS Today! (NYSE:LLY)
arseblog.com - February 16 at 10:53 PM
News IconLilly/Incite’s New JAK Inhibitor, Barincitinib, Shows Promise (NYSE:LLY)
carlascorner.wordpress.com - February 16 at 10:53 PM
News IconStendra Vs Viagra - Generic Cialis Online - Cialis Price - 7,206 Completed ORDERS Today! (NYSE:LLY)
www.interfanzone.com - February 16 at 10:53 PM
businesswire.com logoUnited States Insulin Delivery Market Outlook to 2022: Key Players are Medtronic, Becton Dickinson and Co, Eli Lilly and Company, Novo Nordisk - Research and Markets (NYSE:LLY)
www.businesswire.com - February 16 at 10:53 PM
News IconGrifulvin V 500 Mg - Grifulvin Online - Griseofulvin Oral Suspension Cost - 5,384 Completed ORDERS Today! (NYSE:LLY)
gamingillustrated.com - February 16 at 10:53 PM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Berkshire Hathaway, Eli Lilly, T-Mobile, Oracle and Marathon Petroleum (NYSE:LLY)
finance.yahoo.com - February 16 at 5:51 PM
finance.yahoo.com logoWhat's Driving Lilly's (LLY) Shares after 2016 Decline? (NYSE:LLY)
finance.yahoo.com - February 16 at 5:51 PM
News IconAcivir Cream - Acivir 400 - Acivir 200 Dt - 4,226 Completed ORDERS Today! (NYSE:LLY)
www.blueskyexecutiveaviation.co.uk - February 15 at 5:49 AM
News IconWhat Happens If A Girl Takes Viagra - Free Cialis - Generic Viagra - 3,253 Completed ORDERS Today! (NYSE:LLY)
www.thevegspace.co.uk - February 15 at 12:48 AM
News IconPrilosec And Dementia - Prinivil Zestril - Prinivil Medication - 1,726 Completed ORDERS Today! (NYSE:LLY)
news.arseblog.com - February 14 at 7:47 PM
News IconGeneric Viagra - Tadalafil Online - Viagra Definition - 9,527 Completed ORDERS Today! (NYSE:LLY)
destinationluxury.com - February 14 at 7:47 PM
finance.yahoo.com logoLilly's Olumiant Gets Marketing Authorization in Europe (NYSE:LLY)
finance.yahoo.com - February 14 at 7:47 PM
finance.yahoo.com logoMerck to halt study of mild to moderate Alzheimer's drug (NYSE:LLY)
finance.yahoo.com - February 14 at 7:47 PM
wsj.com logoMerck Stops Clinical Trial of Alzheimer's Drug (NYSE:LLY)
www.wsj.com - February 14 at 7:47 PM
finance.yahoo.com logoMerck stopping late stage study as another Alzheimer's drug fails (NYSE:LLY)
finance.yahoo.com - February 14 at 7:47 PM
News IconWhat Is Bactrim - Bactrim Ds 800 160 - Bactrim And Alcohol - 4,550 Completed ORDERS Today! (NYSE:LLY)
news.arseblog.com - February 14 at 5:26 AM
News IconGeneric Viagra Without A Doctor Prescription - viagra and alcohol - how much is viagra - 6,492 Completed ORDERS Today! (NYSE:LLY)
www.hollywoodnewsdaily.com - February 14 at 12:24 AM
News IconWhere Is The Closest Cvs Pharmacy - Ocean Park Pharmacy - Tschiffely Pharmacy - 4,466 Completed ORDERS Today! (NYSE:LLY)
www.lusakatimes.com - February 14 at 12:24 AM
News IconAnalyst Insights on Price Reaction History: Eli Lilly and Co (NYSE:LLY) (NYSE:LLY)
xboxonezone.com - February 14 at 12:24 AM


What is Eli Lilly and Company's stock symbol?

Eli Lilly and Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How often does Eli Lilly and Company pay dividends? What is the dividend yield for Eli Lilly and Company?

Eli Lilly and Company announced a quarterly dividend on Tuesday, December 13th. Investors of record on Wednesday, February 15th will be given a dividend of $0.52 per share on Friday, March 10th. This represents a $2.08 annualized dividend and a dividend yield of 2.59%. The ex-dividend date is Monday, February 13th. This is a positive change from Eli Lilly and Company's previous quarterly dividend of $0.51.

Where is Eli Lilly and Company's stock going? Where will Eli Lilly and Company's stock price be in 2017?

15 equities research analysts have issued 1-year price targets for Eli Lilly and Company's shares. Their forecasts range from $73.00 to $100.00. On average, they anticipate Eli Lilly and Company's stock price to reach $87.45 in the next year.

When will Eli Lilly and Company announce their earnings?

Eli Lilly and Company is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.

What are analysts saying about Eli Lilly and Company stock?

Here are some recent quotes from research analysts about Eli Lilly and Company stock:

  • According to Zacks Investment Research, "Lilly’s fourth-quarter results were mixed with earnings missing estimates but revenues beating the same.   Earnings jumped 22% year over year backed by strong diabetes sales. In 2017, while new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo are expected to see higher revenues, Lilly expects some established products like Trajenta, Forteo and Humalog to continue doing well. Lilly expects to launch 20 new products between 2014 and 2023, including the launch of at least two new indications/line extensions on an average every year. Although the stock’s decline was sharper than the large cap pharma industry in 2016, it has done well in 2017. However, Alimta will continue to be impacted by competition. Other headwinds include competition from immuno-oncology agents as well as loss of exclusivity for many drugs in the emerging markets." (2/15/2017)

  • J P Morgan Chase & Co analysts commented, "While the FDA recommends both cognitive and function endpoints for Alzheimer's drug approvals, we would not be surprised to see a positive cognitive endpoint and a trend towards functional benefit ultimately being sufficient for approval," analyst Chris Schott wrote in a note.Outcomes And ProbabilitiesThe analyst sees more than 15 percent upside in the stock if EXP-3 study meets both primary and secondary endpoints, which he states are between a 10–20 percent probability.The analyst expects a more muted 10 percent upside if the study hits on its primary but only shows a trend on secondary endpoints (50–60 percent probability).Further, Schott predicts a 10 percent drop in stock if the study fails both endpoints (about 30 percent probability).Moreover, irrespective of the outcome of solanezumab, Schott sees a diverse range of new product opportunities supporting Eli Lilly's greater than 5 percent top-line growth target. Related Link: Apple, Eli Lilly, U.S. Steel: Fast Money Picks For September 7The analyst forecast about 6 percent top-line growth through 2020, with about 5 percent excluding risk adjusted solanezumab sales.The analyst's sales growth target is also supported by a number of $1+ billion product opportunities such as Trulicity, Jardiance, Taltz, baricitinib and abemaciclib."In aggregate, we forecast recent/upcoming new product launches to generate $11.4 billion in sales by 2020," (9/8/2016)

Who owns Eli Lilly and Company stock?

Eli Lilly and Company's stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (3.89%), Franklin Resources Inc. (3.24%), Janus Capital Management LLC (0.79%), Asset Management One Co. Ltd. (0.16%), New York State Teachers Retirement System (0.16%) and Dimensional Fund Advisors LP (0.16%). Company insiders that own Eli Lilly and Company stock include Alfonso G Zulueta, David A Ricks, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, R David Hoover, Stephen F Fry and Susan Mahony.

Who sold Eli Lilly and Company stock? Who is selling Eli Lilly and Company stock?

Eli Lilly and Company's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Fred Alger Management Inc., Capital Guardian Trust Co., Janus Capital Management LLC, Cadinha & Co. LLC, Gabelli Funds LLC, Capital International Ltd. CA and Martingale Asset Management L P. Company insiders that have sold Eli Lilly and Company stock in the last year include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes and Susan Mahony.

Who bought Eli Lilly and Company stock? Who is buying Eli Lilly and Company stock?

Eli Lilly and Company's stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., State Street Corp, Asset Management One Co. Ltd., Alyeska Investment Group L.P., Russell Investments Group Ltd., DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, Renaissance Technologies LLC and Marshall Wace LLP. Company insiders that have bought Eli Lilly and Company stock in the last two years include Jackson P Tai and R David Hoover.

How do I buy Eli Lilly and Company stock?

Shares of Eli Lilly and Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Eli Lilly and Company stock cost?

One share of Eli Lilly and Company stock can currently be purchased for approximately $80.39.

Eli Lilly and Company (NYSE:LLY) Chart for Tuesday, February, 21, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Earnings History Chart

Earnings by Quarter for Eli Lilly and Company (NYSE:LLY)

Dividend History Chart

Dividend Payments by Quarter for Eli Lilly and Company (NYSE:LLY)

Last Updated on 2/21/2017 by MarketBeat.com Staff